Overcoming the poor water solubility of small-molecule drugs is a major challenge in the development of clinical pharmaceuticals. Amorphization of crystalline drugs is a highly effective strategy to improve their aqueous solubility. However, amorphous drugs are thermodynamically unstable and likely to crystallize during manufacturing and storage. Recently, drug–drug co-amorphous systems have emerged as a novel strategy to not only enable enhanced dissolution and physical stability of the individual drugs within the system but also to provide a strategy for combination therapy of the same or different clinical indications. This review serves to highlight advances in the methods used to manufacture and characterize drug–drug co-amorphous systems, summarize drug–drug co-amorphous applications reported in recent decades, and provide an outlook on future possibilities and perspectives.

Teaser

This review serves to highlight advances in the methods used to manufacture and characterize drug–drug CAM systems, summarize their recently reported applications, and discuss the future perspectives of this strategy.

克服小分子药物水溶性差是临床药物开发的一大挑战。结晶药物的非晶化是提高其水溶性的高效策略。然而，无定形药物热力学不稳定，在制造和储存过程中可能会结晶。最近，药物-药物共无定形系统已成为一种新策略，不仅能够增强系统内单个药物的溶出度和物理稳定性，而且还为相同或不同临床适应症的联合治疗提供策略。本综述旨在重点介绍用于制造和表征药物-药物共无定形系统的方法的进展，总结近几十年来报道的药物-药物共无定形应用，并提供对未来可能性和前景的展望。

预告片

本综述旨在重点介绍用于制造和表征药物-药物 CAM 系统的方法的进展，总结其最近报道的应用，并讨论该策略的未来前景。